AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16502768
Drug: EZE 10
RxNorm normalized name: Angeze 10 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE 10 mg + SIMVA 10 mg
Trial: 16502768
Drug: EZE/SIMVA 10/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA 10/80 mg/mg
Trial: 16502768
Drug: EZE 10
RxNorm normalized name: Angeze 10 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE 10 mg + SIMVA 80 mg
Trial: 15337642
Drug: Pharmacotherapy for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy for suicidal behavior
Trial: 1998637
Drug: External cephalic
RxNorm normalized name: Cephaelis ipecacuanha preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External cephalic version (ECV) attempted after intravenous injection of 10 micrograms of hexaprenaline.
Trial: 389121
Drug: Disulfiram (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (250 mg)
Trial: 19682376
Drug: NP 06‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP 06‐1 (Phellodendron amurense bark and Citrus sinensis peel) 740 mg/day (two capsules of 370 mg each, twice daily)
Trial: 12385434
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of omeprazole, amoxicillin, and clarithromycin for 1 week
Trial: 8556078
Drug: Follicle stimulating
RxNorm normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follicle stimulating hormone (FSH)
Trial: 2256497
Drug: Continuous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous oxytocin (intravenous infusion)
Trial: 7001489
Drug: Frusemide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 40 mg twice daily
Trial: 7001489
Drug: Frusemide 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 60 mg twice daily
Trial: 7001489
Drug: Frusemide 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 80 mg twice daily
Trial: 22624284
Drug: RoboLeader (intelligent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RoboLeader (intelligent agent) perfectly reliable
Trial: 22624284
Drug: RoboLeader (intelligent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RoboLeader (intelligent agent) false-alarm prone (60% reliability)
Trial: 22624284
Drug: RoboLeader (intelligent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RoboLeader (intelligent agent) miss prone (60% reliability)
Trial: 22624284
Drug: RoboLeader (intelligent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RoboLeader (intelligent agent) false-alarm prone (90% reliability)
Trial: 22624284
Drug: RoboLeader (intelligent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RoboLeader (intelligent agent) miss prone (90% reliability)
Trial: 16061831
Drug: PEG-GHRH (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-GHRH (0.25, 0.5, 2 or 4 mg)
Trial: 12695732
Drug: Soteria treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soteria treatment (minimal use of antipsychotic medication)
Trial: 12695732
Drug: Usual hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual hospital treatment (control)
Trial: 1835731
Drug: alpha-interferon (alpha-IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alpha-interferon (alpha-IFN) at a standard dose of 5 MU QD or 9 MU t.i.w. for at least 1 year
Trial: 1835731
Drug: alpha-interferon (alpha-IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alpha-interferon (alpha-IFN) therapy
Trial: 7044880
Drug: 15(R)-15-methyl prostaglandin
RxNorm normalized name: 15(S)-15-Methyl Prostaglandin F2α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15(R)-15-methyl prostaglandin E2 (arbaprostil) 100 microgram capsules, taken four times a day for 28 days
Trial: 7044880
Drug: Placebo capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, taken four times a day for 28 days
Trial: 29098261
Drug: Micro-implant anchorage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-implant anchorage
Trial: 26207431
Drug: PCEA: Combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA: Combined spinal-epidural anesthesia (CSE) with a PCEA of ropivacaine 0.1% + sufentanil 0.5 μg/mL for 24 hours after CS
Trial: 26207431
Drug: ED: CSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ED: CSE with an ED bolus of 3 mg morphine after CS
Trial: 26207431
Drug: IT: spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT: spinal anesthesia with an IT bolus of 0.1 mg morphine before CS
Trial: 24418597
Drug: Intensive smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive smoking cessation intervention (tailored counselling during face-to-face visits, weekly for the first four weeks, monthly to six months, and two monthly to 12 months)
Trial: 22133450
Drug: Wait-listed control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-listed control group (treatment as usual)
Trial: 19648310
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% diclofenac sodium gel (Voltaren Gel)
Trial: 12811362
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (250 mL)
Trial: 9570605
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine (30 mg initial bolus, 6 mL)
Trial: 9570605
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine (30 mg initial bolus, 0.6 mL)
Trial: 7923311
Drug: Intra-arterial antibiotic
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial antibiotic infusion therapy (Group A)
Trial: 7923311
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion therapy plus percutaneous drainage of the abscess (Group B)
Trial: 7923311
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics alone (Group C)
Trial: 3144165
Drug: Encainide (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encainide (75 to 240 mg/day)
Trial: 30791874
Drug: Social Behaviour
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Behaviour and Network Therapy
Trial: 19922128
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day glatiramer acetate (GA)
Trial: 8437319
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual conservative therapy)
Trial: 3518048
Drug: Ceftazidime plus
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime plus tobramycin (150 mg/kg body weight/24 h ceftazidime + 10 mg/kg body weight/24 h tobramycin)
Trial: 3518048
Drug: Ceftazidime alone
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime alone (150 mg/kg body weight/24 h)
Trial: 30898322
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (arm C)
Trial: 30578206
Drug: E0302 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E0302 50 mg intramuscular injection twice a week for 16 weeks
Trial: 24120303
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (risperidone or aripiprazole)
Trial: 22969201
Drug: Faringel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faringel (10 mL)
Trial: 19958532
Drug: CVVH at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVVH at 4 L/h for 60 min then 2 L/h
Trial: 19958532
Drug: CVVH at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVVH at 2 L/h for 60 min then 4 L/h
Trial: 17332197
Drug: Delayed cord
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed cord clamping (60 to 90 seconds) with maternal administration of syntocinon
Trial: 7994616
Drug: Topical calcipotriol
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriol (CPT) and sub-therapeutic doses of cyclosporine A (CsA) at 2mg/kg/d
Trial: 23446684
Drug: Pridopidine 45
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 45 mg/day
Trial: 23446684
Drug: Pridopidine (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine (combined 45 mg/day and 90 mg/day)
Trial: 12809962
Drug: Metoclopramide 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.2 mg/kg IV
Trial: 9212119
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac 10 mg every 6 h for up to 3 days
Trial: 9212119
Drug: Hydrocodone 7.5
RxNorm normalized name: HYDROCODONE 7.5/IBUPROFEN 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone 7.5 mg plus acetaminophen 750 mg every 6 h for up to 3 days
Trial: 9212119
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules followed by ketorolac 10 mg every 6 h for up to 3 days
Trial: 31491535
Drug: Retrieval of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrieval of online Problem‐Solving Therapy (PST) sessions
Trial: 31491535
Drug: Rehearsal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehearsal of online Problem‐Solving Therapy (PST) sessions
Trial: 26116425
Drug: Erdosteine 900
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine 900 mg/day
Trial: 26116425
Drug: Erdosteine 600
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine 600 mg/day
Trial: 23860343
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 150 mg/kg infusion
Trial: 21663622
Drug: Standard macronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard macronutrient content (maximum protein 2.8 g/kg/day; lipid 2.8 g/kg/day, dextrose 10%)
Trial: 21663622
Drug: Higher macronutrient
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher macronutrient content (maximum protein 3.8 g/kg/day; lipid 3.8 g/kg/day, dextrose 12%)
Trial: 16598443
Drug: Carvedilol (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (12.5 mg orally before PCI, uptitrated to 50 mg daily)
Trial: 16598443
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 mg orally before PCI, uptitrated to 150 mg daily)
Trial: 9430864
Drug: HighBic. (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HighBic. (40 mmol/l) bicarbonate dialysate
Trial: 9430864
Drug: LowBic. (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LowBic. (30 mmol/l) bicarbonate dialysate
Trial: 3799495
Drug: Pumpkin-seed supplementation
RxNorm normalized name: PUMPKIN SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pumpkin-seed supplementation 60 mg X kg body wt-1 X day-1
Trial: 3799495
Drug: Orthophosphate supplementation
RxNorm normalized name: FERRIC ORTHOPHOSPHATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthophosphate supplementation 60 mg X kg body wt-1 X day-1
Trial: 3799495
Drug: Oxalate supplementation
RxNorm normalized name: oxalate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxalate supplementation 5 mg X kg-1 body wt X day-1
Trial: 6731261
Drug: Control (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (before treatment)
Trial: 27483038
Drug: Calcium +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium + Vitamin D supplementation (1,000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily)
Trial: 15711271
Drug: Ketoconazole (KT)
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole (KT) plus hydrocortisone (H) plus alendronate (AL) (1,200 mg daily KT, 30 mg daily H, 40 mg daily AL)
Trial: 15711271
Drug: Ketoconazole (KT)
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole (KT) plus hydrocortisone (H) (1,200 mg daily KT, 30 mg daily H)
Trial: 8843295
Drug: Rifampin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (300 mg daily for 14 days)
Trial: 3881051
Drug: 0.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 mg of oral physostigmine
Trial: 3881051
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of oral physostigmine
Trial: 3881051
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg of oral physostigmine
Trial: 3881051
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg of oral physostigmine
Trial: 3881051
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg of oral physostigmine
Trial: 3881051
Drug: Dose associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose associated with least severe symptoms
Trial: 24660159
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (15 mg/kg)
Trial: 23522247
Drug: lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine treatment (n=164)
Trial: 18671947
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (calcium plus A. senticosus)
Trial: 15986343
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice a day for 30 months
Trial: 12566640
Drug: 10% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sucrose rinse, 5 times daily
Trial: 12566640
Drug: 10% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sucrose rinse, 10 times daily
Trial: 12566640
Drug: 5% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sucrose rinse, 5 times daily
Trial: 10336571
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg tablet (fasted)
Trial: 10336571
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg tablet (fed)
Trial: 10336571
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg intravenous (i.v.) infusion over 40 min (fasted)
Trial: 26216386
Drug: SP3 (S‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP3 (S‐1 80 mg/m2/day on days 1‐14 and cisplatin 60 mg/m2 on day 1)
Trial: 26216386
Drug: SP5 (S‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP5 (S‐1 80‐120 mg/day on days 1‐21 and cisplatin 60 mg/m2 on day 1 or 8)
Trial: 19405802
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Local infiltration of port sites with 10 mL of ropivacaine
Trial: 19405802
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Infiltration of port sites with 10 mL of ropivacaine and intraperitoneal instillation of 10 mL of ropivacaine
Trial: 19405802
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: No analgesic treatment
Trial: 15457308
Drug: Self-management (SM)
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management (SM) of warfarin using a point-of-care device (Pro Time Microcogulation System)
Trial: 15457308
Drug: Physician-management (PM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-management (PM) of warfarin
Trial: 11206237
Drug: Fexofenadine and
RxNorm normalized name: Fexofenadine and pseudoephedrine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine and montelukast administered concurrently
Trial: 9542492
Drug: Ibopamine plus
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine plus prazosin (200 mg single dose)
Trial: 336110
Drug: d.1 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d.1 5 hydroxy-tryptophan (600 mg a day)
Trial: 28327896
Drug: Infusional bleomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusional bleomycin (90,000 units infusion over 72 hours)
Trial: 28327896
Drug: Conventional BEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional BEP with weekly bleomycin (30,000 units/week i.v. bolus)
Trial: 28327896
Drug: Conventional BEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional BEP with weekly bleomycin
Trial: 23236022
Drug: 500 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg/d cyanocobalamin for 8 weeks
Trial: 23236022
Drug: 100 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg/d cyanocobalamin for 8 weeks
Trial: 23236022
Drug: 10 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg/d cyanocobalamin for 8 weeks
Trial: 19345767
Drug: Behavioral medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral medicine intervention
Trial: 15338504
Drug: Lumiracoxib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 200 mg qd
Trial: 15338504
Drug: Lumiracoxib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 400 mg qd
Trial: 2738720
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (IVIG) 750 mg/kg
Trial: 29271278
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (50,000 IU of oral vitamin D3 once weekly)
Trial: 27593544
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (Ecologic Barrier, Winclove, Amsterdam, The Netherlands) daily for 6 months
Trial: 23425142
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin ointment and chlorhexidine body wash (treated carriers)
Trial: 23425142
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (untreated carriers)
Trial: 23425142
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (non-carriers)
Trial: 20015040
Drug: 11β-HSD1 selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11β-HSD1 selective inhibitors (e.g., DIO-902, INCB13739)
Trial: 19100003
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg plus Hydrochlorothiazide 12.5 mg (TH)
Trial: 19100003
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg (T)
Trial: 15723265
Drug: Aspirin (acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (acetylsalicylic acid, ASA)
Trial: 11853119
Drug: bromperidol (6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromperidol (6, 12 or 18 mg/day) for 3 weeks
Trial: 30039387
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry tablets alone
Trial: 30039387
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry tablets containing vitamin C
Trial: 25010824
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy combined with pulsed radiofrequency (PRF) lesioning of the suprascapular nerve (SSN) for 12 weeks.
Trial: 25010824
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy alone for 12 weeks.
Trial: 19774311
Drug: Qigong intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qigong intervention (twice a week for 12 weeks)
Trial: 16391401
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) for 3 months in SPS
Trial: 16391401
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) for 3 months in DM